Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 28, 2015 11:16 AM ET

Pharmaceuticals

Company Overview of Sunovion Pharmaceuticals Inc.

Company Overview

Sunovion Pharmaceuticals Inc. is a research-based pharmaceutical company that is engaged in discovering, developing, and commercializing therapeutic products to help patients suffering from central nervous system (CNS) and respiratory disorders, as well as other illnesses. It focuses on treating various CNS conditions, such as anxiety, insomnia, bipolar depression, epilepsy, and schizophrenia. The company offers Latuda (lurasidone HCl) tablets for the treatment of adult patients with depressive episodes associated with bipolar I disorder, as well as with schizophrenia; Aptiom (eslicarbazepine acetate) tablet, an antiepileptic drug for use as adjunctive treatment of partial-onset seizures; an...

84 Waterford Drive

Marlborough, MA 01752

United States

Founded in 1984

2,400 Employees

Phone:

508-481-6700

Fax:

508-481-7683

Key Executives for Sunovion Pharmaceuticals Inc.

Vice Chair, President and Head of Global Clinical Development - Sumitomo Dainippon Pharma Group
Chief Financial Officer and Senior Vice President
Chief Administrative Officer and Executive Vice President
Chief Compliance & Ethics Officer and Senior Vice President
Chief Medical Officer and Executive Vice President
Compensation as of Fiscal Year 2014.

Sunovion Pharmaceuticals Inc. Key Developments

Sunovion Pharmaceuticals Announces Results of Two Health Outcomes Studies and Placebo Controlled Randomized Trial

Sunovion Pharmaceuticals Inc. announced the results of two health outcomes studies and a placebo controlled randomized trial presented at the American Thoracic Society (ATS) 2015 Annual Meeting in Denver. Results from these studies demonstrated that a substantial proportion of hospitalized chronic obstructive pulmonary disease (COPD) patients are not provided maintenance treatments; one in three patients report low confidence in using COPD devices and a majority of these patients have low treatment adherence; and more patients on Brovana (arformoterol tartrate) Inhalation Solution reported clinically significant improvements in health-status compared with placebo. Treatment Patterns for Inpatients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease (Poster Board #P620) In a retrospective analysis of claims data collected from more than 500 hospitals across the U.S. in 2012, inpatient treatment patterns for patients hospitalized with acute exacerbations of COPD indicated that 78.2% were treated with multiple bronchodilators. Only 52.5% of patients received long-acting bronchodilators while hospitalized, although the Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) guidelines state that in the hospital prior to discharge, patients should start long-acting bronchodilators, either beta2-agonists and/or anticholinergics with or without inhaled corticosteroids.

Sunovion Pharmaceuticals Inc. Announces Positive Results for Latuda® (lurasidone HCl) in First Placebo-Controlled Trial of Patients with Major Depressive Disorder with Mixed (Subsyndromal Hypomanic) Features

Sunovion Pharmaceuticals Inc. announced results from the first placebo-controlled study in adults with major depressive disorder (MDD) who presented with a limited number of associated manic symptoms (mixed features). This study demonstrated that Latuda® (lurasidone HCl) significantly reduced depressive symptoms in adults with MDD with mixed features when compared to placebo. The study results were presented at the 168th Annual Meeting of the American Psychiatric Association (APA). LATUDA is an atypical antipsychotic agent indicated in the United States for the treatment of adult patients with major depressive episodes associated with bipolar I disorder (bipolar depression) both as monotherapy and as adjunctive therapy with lithium or valproate, and for the treatment of adult patients with schizophrenia. In this randomized, double-blind, placebo-controlled, 6-week clinical trial, adults patients with MDD with a limited number of manic symptoms (mixed features) were randomized to receive 6 weeks of treatment with flexibly-dosed LATUDA 20 " 60 mg/day (N=109) or placebo (N=102). The primary efficacy endpoint in the study was change from baseline at Week 6 in Montgomery-Asberg Depression Rating Scale (MADRS) total score. The key secondary endpoint was change from baseline at Week 6 in the Clinical Global Impression, Severity (CGI-S) score, which assessed global severity of illness.

Sunovion Reports Earnings Results for the Full Year Ended March 31, 2015

Sunovion reported earnings results for the full year ended March 31, 2015. For the year, the company reported net sales of JPY 141 billion compared to JPY 149.9 billion a year ago. Operating income was JPY 15.0 billion compared to JPY 20.1 billion a year ago. Ordinary income was JPY 15.3 billion compared to JPY 20.3 billion a year ago. Net income was JPY 5.9 billion compared to JPY 8.2 billion a year ago.

Similar Private Companies By Industry

Company Name Region
Health Decisions, Inc. United States
Heaven Sent Naturals, Inc. United States
Good 'n' Natural Manufacturing Corp. United States
Simply H, LLC United States
Conforma Therapeutics Corporation United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Sunovion Pharmaceuticals Inc., please visit www.sunovion.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.